Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

You‐Quan Li, Anhui Shi, Fuhai Li, Rong Yu, Guangying ZhuChinese 2011 · DOI

Abstract

Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m(2) docetaxel and 60mg/m(2) cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.
BibTeX
@inproceedings{li2011phase,
  author = {You‐Quan Li and Anhui Shi and Fuhai Li and Rong Yu and Guangying Zhu},
  title = {{Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer}},
  booktitle = {Chinese},
  year = {2011},
  doi = {10.1007/s11670-011-0129-9},
}

Loading related content...

Figure